Searched for
IMMUNOGENICITY
Bharat Biotech starts clinical trials of TB jabThe only vaccine in use today--BCG (Bacillus Calmette and Guerin)--is an attenuated variant of the bovine TB pathogen. This is more than a ...- Covaxin safe for kids aged 2-18, found as effective as in adults: LancetThe data were submitted to India's Central Drugs Standard Control Organisation in October 2021 and the vaccine has received its approval fo...
- Covaxin proven safe for children of 2-18 years age group in phase III study: Bharat BiotechThe clinical trial conducted in the pediatric population has shown safety, less reactogenic, and robust immunogenicity. The data was submit...
- Biological E asked to give more info on Corbevax for 5-12 year-oldsBiological E had presented interim safety and immunogenicity data of phase 2/3 clinical trials conducted on participants aged 5 to 18 years.
- Data required for suggesting mixing of COVID-19 vaccine:GovtThe Central Drugs Standard Control Organization (CDSCO) has granted permission to the Christian Medical College, Vellore to conduct phase-I...
- Covaxin safe and immunogenic in 2-18 age group, says Bharat BiotechThe Hyderabad-based company had conducted phase-2/3, open-label, and multi-centre studies to evaluate the safety, reactogenicity, and immun...
- Covaxin for Children: Study says robust safety, immunogenicity in 2-18 year old volunteersBharat Biotech had conducted phase II/III, open-label, and multicenter studies to evaluate the safety, reactogenicity, and immunogenicity o...
- DCGI nod to phase-I clinical trial of COVID-19 vaccine of Reliance Life SciencesThe firm is required to submit the revised clinical trial protocol for immunogenicity to be assessed on Day 42, instead of Day 14, as recom...
- Apollo hospitals MD calls Covaxin, Covishield combination results 'encouraging'Covaxin contains dead virus of Covid which triggers the immune system to draw up a defense system against Covid while Covishield is vector ...
- Mixing Covishield, Covaxin shots gives better result: ICMR studyA total of 98 vaccine recipients — having completed two weeks or more after the second dose — were included in the study.
- Mix of Covishield, Covaxin yields better results, finds ICMR StudyThe study titled ‘Serendipitous COVID-19 Vaccine-Mix in Uttar Pradesh, India: Safety and Immunogenicity Assessment of a Heterologous Regime...
- Zydus vaccine under close review, approval likely to get delayedZydus had applied for emergency use authorisation (EUA) for its vaccine on July 1, but it is yet to be taken up by the subject expert commi...
- Dr Reddy's Labs denied approval for final trial of Russian-made Sputnik Light"The subject expert committee (SEC), a body under the drug regulator, did not find any "scientific rationale" to conduct phase-3 trials and...
- During pandemic, vaccine’s restricted use considered based on safety, immunogenicity data: ICMR chiefDrugs Controller General of India (DCGI) had on Sunday approved Oxford COVID-19 vaccine Covishield, manufactured by the Serum Institute, an...
- DCGI approves SII's Covishield and Bharat Biotech's Covaxin for restrictive use in emergency situationThe subject expert committee had given conditional nod to both the vaccines and these were awaiting the drug regulator's approval.
- Zydus Cadila seeks govt nod to start Phase-III clinical trials of COVID-19 vaccineThe Phase-II study of the vaccine, ZyCoV-D, had been conducted in over 1,000 healthy adult volunteers as part of the adaptive Phase-I and I...
- Oxford COVID-19 vaccine produces immune response among elderly and young, AstraZeneca saysA vaccine that works is seen as a game-changer in the battle against the novel coronavirus, which has killed more than 1.15 million people,...
- Serum Institute of India gets approval to start human trials for Oxford vaccineEarlier this week, a committee of experts had deferred a decision on the request of SII to start trials and asked the company to amend its ...
- Zydus Cadila begins human trials of its COVID-19 vaccine, aims for an early 2021 launchThe company said in the preclinical stage the vaccine was found to be safe, immunogenic and well-tolerated. It was also able to produce neu...
- Expect Covid vaccine human trial to be completed in 3 months: Zydus Cadila Chairman‘We did a detailed 28-day toxicity study in two different animal species’
Load More
